Notably, our previous work comparing the TfRMAb-TNFR and etanercept at a twofold higher dose (3 mg/kg) showed more robust effects of the TfRMAb-TNFR than etanercept in the male APP/PS1 mouse model of amyloidosis [42]. This evidence concerns the gene TNFRSF1A and amyloidosis.